View Older Stories
-
TD Cowen on Abbott Labs (ABT): 'The Stage is Set for a Stronger 2H'
-
U.S. MedTech stocks: Q3 earnings preview
-
Rothschild Redburn Upgrades Abbott Labs (ABT) to Buy
-
Abbott (ABT) Declares $0.63 Quarterly Dividend; 2.5% Yield
-
Abbott to pay $385 million to settle DOJ infant formula claims
-
Abbott to pay $385M to settle contaminated infant formula allegations
-
Abbott launches whole milk ready-to-feed infant formula in the U.S.
-
Abbott wins FDA clearance for dual glucose-ketone diabetes sensor
-
Abbott Labs (ABT) PT Raised to $135 at TD Cowen
-
Abbott settles preterm formula NEC lawsuits for $670 million
-
Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
-
Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle
-
Wolfe Research Upgrades Abbott Labs (ABT) to Outperform
-
Abbott and Google Health partner on glucose monitoring and AI health tools
-
Abbott Labs (ABT) Reiterated at Buy by Benchmark After Q2 Model Updates
-
Abbott Labs (ABT) Reiterated at Buy by Benchmark After Q2 Revenue Beat
-
Abbott Labs (ABT) PT Raised to $134 at BTIG
-
Abbott beats second-quarter estimates, raises 2026 guidance
-
Abbott (ABT) Tops Q2 EPS by 3c; offers guidance
-
Abbott (ABT) call put ratio 1 call to 1.3 puts into quarter results
-
Benchmark Reiterates Buy Rating on Abbott Labs (ABT) Ahead of Q2 Results
-
U.S. MedTech stocks: Q2 earnings preview
-
Reckitt Unit Cleared By Jury In Premature-infant Formula Case - Bloomberg
-
Baird Starts Abbott Labs (ABT) at Outperform, 'Set to Improve with Catalysts Ahead'
-
Piper Sandler on Abbott Labs (ABT): 'A Name Worth Revisiting'
-
Abbott (ABT) Declares $0.63 Quarterly Dividend; 2.9% Yield
-
Abbott study finds diabetic ketoacidosis often goes unrecognized
-
American Cancer Society reaffirms Abbott colorectal screening tests
-
Goldman Makes Monthly Adjustment to Regional Directors' Cut List in US
-
Abbott Labs (ABT) PT Lowered to $106 at Leerink Partners
-
Abbott Labs (ABT) PT Lowered to $110; Bernstein: 'Good entry point, or value trap?'
-
Abbott Labs (ABT) PT Lowered to $115 at Piper Sandler After a 'Disappointing Q1'
-
Abbott Labs (ABT) PT Lowered to $115 at TD Cowen
-
Abbott Labs (ABT) PT Lowered to $130 at RBC Capital
-
Abbott Labs (ABT) PT Lowered to $110 at Bernstein SocGen Group
-
Abbott Labs (ABT) PT Lowered to $120 at Stifel Following Q1 Results
-
Abbott Labs (ABT) PT Lowered to $115 at Oppenheimer
-
Abbott Labs (ABT) PT Lowered to $120 at Benchmark on Updated Guidance
-
Abbott Labs (ABT) PT Lowered to $120 at BofA Securities
-
Abbott (ABT) 51K contracts, compared to its 90-day average of 15K contracts, share price down 5.3%
-
Leerink Partners on Abbott Labs (ABT): U.S. MedTech softness could be viewed unfavorably
-
Abbott shares dip on soft current-quarter guide; Q1 results in line
-
Abbott (ABT) Reports In-Line Q1 EPS; offers guidance
-
Abbott (ABT) call put ratio 1.5 calls to 1 put into quarter results
-
TD Cowen: 'Abbott Labs (ABT) Stock Reaction Overdone'
-
Abbott Owes $17 Million Punitive Damages In Baby-formula Trial - Bloomberg
-
Abbott integrates precision oncology tests with Flatiron's OncoEMR platform
-
UBS Reiterates Buy Rating on Abbott Labs (ABT) on DD Medical Device Growth Sustainability
-
Abbott Labs (ABT) Reiterated at Buy by Benchmark After FreeDM Trial Results
-
Piper Sandler's Key Takeaways From CRT 2026


